IRTC — iRhythm Technologies, Inc. stock price, charts and financials

QT38iRhythm Technologies, Inc.

iRhythm Technologies, Inc. (NASDAQ: IRTC) is a Healthcare company in the Medical - Devices industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
125.26
-2.58-2.02%
OverviewShort InterestFilings
IRTCQT38iRhythm Technologies, Inc.·NASDAQ
125.26-2.02%
News
Down 2.0% — Kuehn Law Encourages Investors of iRhythm Technologies, Inc. to Contact Law Firm (prnewswire.com).
Medium confidence
TA
Loading chart...
Signal & projected range
Earnings big beat — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
LIVN-0.13%$76.12ITGR-0.16%$125.07HAE-1.74%$86.31TMDX+3.02%$86.42AXGN+1.92%$47.32UFPT+1.57%$318.93BFLY+11.72%$9.87ESTA-0.98%$76.66
Snapshot
Index-P/E-EPS (ttm)-0.86Insider Own3.91%Shs Outstand32.86MPerf Week9.11%
Market Cap4.20BForward P/E114.24EPS next Y1.12Insider Trans-9.59%Shs Float30.79MPerf Month8.41%
Enterprise Value4.68BPEG-EPS next Q-Inst Own-Short Float11.14%Perf Quarter2.38%
Income-13.86MP/S5.09EPS this Y99.15%Inst Trans-Short Ratio6.11Perf Half Y-12.89%
Sales825.34MP/B22.61EPS next Y15486.91%ROA-1.28%Short Interest3.43MPerf YTD-27.95%
Book/sh-P/C70.29EPS next 5Y-ROE-8.97%52W High207.73 -39.70%Perf Year-18.06%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-1.05%52W Low98.82 26.76%Perf 3Y26.26%
Dividend Est.-EV/EBITDA-Sales past 3/5Y22.04% 23.03%Gross Margin71.45%Volatility5.82% 4.54%Perf 5Y150.08%
Dividend TTM-EV/Sales5.67EPS Y/Y TTM76.31%Oper. Margin-1.17%ATR (14)5.99Perf 10Y-
Dividend Ex-Date-Quick Ratio3.75Sales Y/Y TTM33.11%Profit Margin-1.69%RSI (14)62.27Recom2.15
Dividend Gr. 3/5Y-Current Ratio3.87EPS Q/Q54.74%SMA209.52%Beta1.30Target Price175.88
Payout0.00%Debt/Eq3.91Sales Q/Q25.16%SMA5011.16%Rel Volume3.09Prev Close127.84
Employees2,400LT Debt/Eq4.67EarningsOct 29SMA200-8.91%Avg Volume591.26KPrice125.26
IPO DateOct 20, 2016Option/ShortYes / YesEPS/Sales Surpr.34.78% 2.72%Net Debt/EBITDA23.91Volume1,827,541Change-2.02%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-07-26ReiteratedEvercore ISIOutperform$150 → $165
Aug-07-26ReiteratedRobert W. Baird$160 → $165
Aug-07-26ReiteratedCanaccord GenuityBuy$157 → $196
Aug-07-26ReiteratedNeedhamBuy$255 → $192
Jul-22-26InitiatedStephensOverweight$160
Jul-16-26ReiteratedTruist SecuritiesBuy$174 → $160
Jul-06-26ReiteratedEvercore ISI GroupOutperform$160 → $150
Jun-01-26ReiteratedCanaccord GenuityBuy$180 → $152
May-01-26ReiteratedTruist FinancialBuy$170 → $174
May-01-26ReiteratedRobert W. Baird$166 → $175
Latest News
Aug-08-26
Aug-08-2603:35PM
Kuehn Law Encourages Investors of iRhythm Technologies, Inc. to Contact Law Firmprnewswire.com
Aug-07-26
Aug-07-2610:47AM
iRhythm Combines Strong Performance with VitalConnect Buy to Expand Remote Cardiac Carebenzinga.com
05:34AM
iRhythm Holdings, Inc. (IRTC) Q2 2026 Earnings Call Transcriptseekingalpha.com
Aug-06-26
Aug-06-2611:36PM
iRhythm Holdings, Inc. (IRTC) Tops Q2 Earnings and Revenue Estimateszacks.com
11:04PM
iRhythm Technologies Q2 Earnings Call Highlightsmarketbeat.com
04:06PM
iRhythm Technologies Q2 Adj. EPS $0.58 Beats $(0.00) Estimate, Sales $224.172M Beat $219.324M EstimateBenzinga
04:05PM
iRhythm Holdings Announces Second Quarter 2026 Financial Resultsglobenewswire.com
08:00AM
Bernstein Litowitz Berger & Grossmann LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of iRhythm Technologies, Inc. Common Stockprnewswire.com
Jul-29-26
Jul-29-2612:00PM
Did iRhythm Technologies, Inc. Insiders Breach their Fiduciary Duties to Shareholders?gurufocus.com
Jul-28-26
Jul-28-2605:10PM
Kuehn Law Encourages Investors of iRhythm Technologies, Inc. to Contact Law Firmglobenewswire.com
03:45AM
Castleark Management LLC Sells 23,000 Shares of iRhythm Technologies $IRTCdefenseworld.net
Jul-27-26
Jul-27-2603:55AM
iRhythm Technologies $IRTC Shares Sold by Bessemer Group Inc.defenseworld.net
Jul-23-26
Jul-23-2602:46PM
Stephens & Co. Initiates Coverage On iRhythm Holdings with Overweight Rating, Announces Price Target of $160Benzinga
Jul-16-26
Jul-16-2604:05PM
iRhythm Holdings to Report Second Quarter 2026 Financial Results on August 6, 2026globenewswire.com
01:13PM
Truist Securities Maintains Buy on iRhythm Holdings, Lowers Price Target to $160Benzinga
Company

iRhythm Technologies, Inc. is a digital healthcare enterprise dedicated to offering portable electrocardiogram (ECG) monitoring solutions to individuals in the United States who face the risk of cardiac arrhythmias. Its primary offering, the Zio service, provides a comprehensive ambulatory cardiac monitoring system. This system ingeniously combines a wireless, patch-based, and wearable biosensor—specifically embodied in products like the Zio XT and AT monitors—with a sophisticated cloud-based data analysis platform. These single-use biosensors precisely record a patient's heartbeats and ECG data, thereby enabling medical professionals to effectively oversee patient heart health and accurately diagnose arrhythmias. Furthermore, iRhythm maintains a strategic development partnership with Verily Life Sciences LLC, focused on pioneering future atrial fibrillation screening, detection, and monitoring innovations. Founded in 2006, the company maintains its corporate headquarters in San Francisco, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue788747592——————
Cost of Goods Sold Incl. D&A229220184——————
Gross Profit559527408——————
Selling, General and Administrative Excl. Other500479419——————
Research and Development8485104——————
Other Operating Expense
-400——————
Operating Income-22-37-116——————
Interest Expense121313——————
Unusual Expense
—————————
Non-Operating Income (Expense)8616——————
Net Income Before Taxes-26-44-113——————
Income Taxes111——————
Consolidated Net Income-27-45-113——————
Net Income From Continuing Operations-27-45-113——————
Net Income-27-45-113——————
EPS (Recurring)-0.86-1.39-3.63——————
EPS (Basic, Before Extraordinaries)-0.86-1.39-3.63——————
EPS (Diluted)-0.86-1.39-3.63——————
EBITDA12-4-74——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio5.257.604.72——————
Gross Margin70.9470.5568.92——————
Operating Margin-2.79-4.95-19.59——————
Net Margin-3.43-6.02-19.09——————
Shares Outstanding333231——————
Market Capitalization4,1345,6782,795——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
$202.37$173.94$145.52$117.10$88.67● Close Price0.00M2.61M5.22M7.83M10.44MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Rodda JulianneEVP, CHIEF PEOPLE OFFICERAug 03 '26Sale122.122,112257,91918,201Aug 04
Smith MervinEVP Strategic Business OpsAug 03 '26Sale122.1261775,34922,410Aug 04
Patterson ChadCHIEF COMM & PRODUCT OFFICERAug 03 '26Sale122.122,712331,19255,629Aug 04
Freeman Sean ClintonEVP, Strategy & Corp DevtJul 02 '26Sale124.71918114,48413,641Jul 06
Turakhia MinangCHIEF MED/SCI OFCR EVP ADVTECHJul 02 '26Sale124.711,423177,46253,620Jul 06
TALWALKAR ABHIJIT YDirectorMay 11 '26Buy10.715,31256,89225,611May 12
TALWALKAR ABHIJIT YDirectorMay 11 '26Sale117.935,312626,43020,299May 12
TALWALKAR ABHIJIT YDirectorMay 11 '26Option Exercise10.715,31256,8920May 12
Lawrence Brian LeeChief Technology OfficerMay 04 '26Sale120.801,014122,49120,154May 05
Smith MervinEVP Strategic Business OpsMar 16 '26Sale114.302,585295,46623,027Mar 17
Turakhia MinangCHIEF MED/SCI OFCR EVP ADVTECHMar 02 '26Sale128.454,027517,25954,906Mar 03
Shrishrimal SumiEVP, Chief Risk OfficerMar 02 '26Sale128.442,830363,48441,870Mar 03
Smith MervinEVP Strategic Business OpsMar 02 '26Sale128.441,352173,65325,612Mar 03
Patterson ChadCHIEF COMM & PRODUCT OFFICERMar 02 '26Sale128.444,444570,80458,164Mar 03
Murphy Patrick MichaelCBO and CLOMar 02 '26Sale128.444,357559,62463,203Mar 03
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.